AbbVie Seeks EMA Approval for SKYRIZI Subcutaneous Induction in Crohn’s Disease
AbbVie Seeks EMA Approval for SKYRIZI Subcutaneous Induction in Crohn’s Disease The Clinical Trial Vanguard
Regulatory Approvals
FDA approves breakthrough pancreatic cancer drug
FDA approves breakthrough pancreatic cancer drug Utah Public Radio
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times
FDA approves groundbreaking new pancreatic cancer drug
FDA approves groundbreaking new pancreatic cancer drug The Hill
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Targeted Oncology